Clinical Trial Update: An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis [Phase 1, Phase 2]

View source ↗

Summary

An open-label Phase 1/2 clinical trial evaluating the safety, efficacy, and cellular kinetics of YTB323 in Relapsing Multiple Sclerosis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• YTB323

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing Multiple Sclerosis | Phase 1, Phase 2 | Status: RECRUITING